ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis.

Lee Hatter Pepa Bruce Irene Braithwaite Mark Holliday James Fingleton Mark Weatherall Richard Beasley

Published in: ERJ open research (2021)

As-needed ICS-formoterol offers a therapeutic alternative to maintenance low-dose ICS plus SABA in asthma and may be the preferred option when prevention of severe exacerbation is the primary aim of treatment.

Keyphrases

chronic obstructive pulmonary disease
low dose
lung function
allergic rhinitis
high dose
intensive care unit
air pollution
acute respiratory distress syndrome
mechanical ventilation